Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Daniela Rusovici

Clinical Neurophysiology Port St John, FL Medical Doctor

NPI 1801964788 CMS profile 36002

5005 Port St John Pkwy, Suite 2200, Port St John, FL 32927

Open in the dashboard

General payments

$2,939

167 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Daniela Rusovici of Port St John, FL is reported in the CMS Open Payments database as having received $2,939 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $14 1
2020 General $547 30
2019 General $2,378 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniela Rusovici
  • Clinical Neurophysiology median
  • Middle half of Clinical Neurophysiology
  • National median

In program year 2025, general payments to Daniela Rusovici were reported at $0. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.

Show as a table
Year Daniela Rusovici Clinical Neurophysiology median Middle half National median
2019 $2,378 $306 $88–$1,636 $163
2020 $547 $299 $85–$1,847 $114
2021 $0 $325 $96–$2,308 $132
2022 $14 $395 $106–$1,957 $149
2023 $0 $388 $120–$1,718 $160
2024 $0 $471 $137–$1,931 $164
2025 $0 $435 $121–$1,917 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Avanir Pharmaceuticals, Inc. $418 28 payments
  2. Alexion Pharmaceuticals, Inc. $272 10 payments
  3. UCB, Inc. $233 11 payments
  4. Novartis Pharmaceuticals Corporation $216 15 payments
  5. Amgen Inc. $215 6 payments
  6. Teva Pharmaceuticals USA, Inc. $212 12 payments
  7. EMD Serono, Inc. $190 11 payments
  8. Genzyme Corporation $139 7 payments
  9. Allergan Inc. $125 8 payments
  10. US WorldMeds, LLC $124 11 payments
  11. Other $795 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,810 165 payments
  2. Education $111 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 1 payment
Products named General payments · program years 2019–2022
  1. NUEDEXTA $410 27 payments
  2. AIMOVIG $280 11 payments
  3. Soliris $272 10 payments
  4. Briviact $233 11 payments
  5. Mavenclad $137 8 payments
  6. APOKYN $124 11 payments
  7. Xadago $124 11 payments
  8. AUBAGIO $114 6 payments
  9. MAYZENT $113 7 payments
  10. NUPLAZID $109 6 payments
  11. Other $1,252 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Neurophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record